Oküler Farmakoloji ve Terapötikler

Sasaki H, Yamamura K, Nishida K, et al. Delivery of drugs to the eye by topical application. Progress in Retinal and Eye Research. 1996;15: 583–620. doi.org/10.1016/1350-9462(96)00014-6

Hämäläinen, KM, Kanasen K, Auriola S, et al. Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva and sclera. Investigative Ophthalmology & Visual Science. 1997;38: 627-634.

Grass GM, Robinson JR. Mechanisms of corneal drug penetration II: ultrastructural analysis of potential pathways for drug movement. Journal of Pharmaceutical Sciences. 1988b;77: 15–23. doi.org/10.1002/jps.2600770104

Sasaki H, Ichikawa M, Yamamura K, et al. Ocular membrane permeability of hydrophilic drugs for ocular peptide delivery. Journal of Pharmacy and Pharmacology. 1997;49: 135–139. doi.org/10.1111/j.2042-7158.1997.tb06767.x

Vane, J, Botting, R. Overview: mechanisms of action of anti‐inflammatory drugs. In: Improved Non‐steroid Anti‐inflammatory Drugs: COX2 Enzyme Inhibitors (eds Vane J, Botting J, Botting R.). Dordrecht: Kluwer Academic Publishers.1995: p. 1-27

Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Advanced Drug Delivery Reviews. 2001;52: 37-48. doi.org/10.1016/S0169-409X(01)00193-4

Grass GM, Robinson JR. Mechanisms of corneal drug penetration I: in vitro and in vivo kinetics. Journal of Pharmaceutical Sciences. 1988a;77: 3-14. doi.org/10.1002/jps.2600770103

Prausnitz MR, Noonan, JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. Journal of Pharmaceutical Sciences.1998;87: 1479–87. doi.org/10.1021/js9802594

Nettey H, Darko Y, Bamiro OA, et al. Ocular barriers. In: Ocular Drug Delivery: Advances, Challenges and Applications (ed Addo R.T.). Cham, Switzerland: Springer International Publishing. 2016. pp. 27–36.

Bellhorn, RW. An overview of the blood–ocular barriers. Veterinary & Comparative Ophthalmology, 1.1991. p. 205–217.

Raviola, G. The structural basis of the blood–ocular barriers. Experimental Eye. 1977. doi.org/10.1016/S0014-4835(77)80009-2

Regnier A, Clode A, Scott EM, et al. Ocular Pharmacology and Therapeutics. Essentials of Veterinary Ophthalmology. Fourth Edition, Ed: Gelatt KN, Plummer CE. John Wiley & Sons, Inc. USA Research, 25(Suppl.). 2022. p. 27-63.

Toda R, Kawazu K, Oyabu M, et al. Comparison of drug permeabilities across the blood‐retinal barrier, blood‐ aqueous humor barrier, and blood brain barrier. Journal of Pharmaceutical Sciences. 2011;100: 3904-11. doi.org/10.1002/jps.22610

Mahajan GB, Balachandran L. Antibacterial agents from actinomycetes-a review. Front Biosci. (Elite Ed). 2012;4: 240-253

Peterson R. Currently available antimicrobial agents and theirpotential for use as monotherapy. Clinical Microbiology and Infection. 2008;14(6): 30-45. oi.org/10.1111/j.1469-0691.2008.02125.x

Gilbert D. Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R, (eds.) Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill: Livingstone;2000.p.307-336.

Miller D. Pharmacological treatment for infectious corneal ulcers. Expert Opinion on Pharmacotherapy. 2013;14(5), 543-560. doi.org/10.1517/14656566.2013.775248

Ophthalmic Antibiotics Therapeutic Class Review (TCR), 2022. Online https://www.hhs.texas.gov/sites/default/files/documents/oct-2023-durb-agenda-item3l.pdf.

Maggs DJ. Ocular Pharmacology And. Slatter’s Fundamentals Of Veterinary Ophthalmology-E-Book.2007: 33

Maurice DM, Mishima S. Ocular pharmacokinetics. In: Pharmacology of the Eye (ed. Sears, ML), Berlin: Springer‐Verlag. 1984. p.19-116

Kim HB, Wang M, Ahmed S, et al. Transferable quinolone resistance in Vibrio cholerae. Antimicrobial agents and chemotherapy. 2010;54(2): 799-803. DOI:https://doi.org/10.1128/aac.01045-09

Herbert R, Caddick M, Somerville T, et al. Potential new fluoroquinolone treatments for suspected bacterial keratitis. BMJ Open Ophthalmology. 2022;7(1). https://doi.org/10.1136/bmjophth-2022-001002

Yazar E. Kemoterapötikler, In: Veteriner İlaç Rehberi ve Tedavi El Kitabı, Ed: Yazar E, Nobeltıp, Istanbul, Türkiye. 2019

Yazar E, Traş B, Elmas M. Florokinolonlar, In: Veteriner İlaç Rehberi, Ed:Yazar E. Nobeltıp, İstanbul., Türkiye. 2023

Wang W, Sasaki H, Chien DS, et al. Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit: a comparison with corneal penetration. Current Eye Research. 1991;6: 571–579. doi.org/10.3109/02713689109001766

Maggs DJ. Ophthalmic medications and therapeutics. Slatter’s Fundamentals of Veterinary Ophthalmology, Fourth edition, Ed: Maggs DJ, Miller PE, Ofri R. 2017. p.51-84.

Cheruvu, NPS, Kompella UB. Bovine and porcine transscleral solute transport: influence of lipophilicity and the choroid‐Bruch’s layer. Investigative Ophthalmology & Visual Science. 2006;47: 4513-22. doi.org/10.1167/iovs.06-0404

Lourenço-Martins AM, Delgado E, Neto I, et al. Allergic conjunctivitis and conjunctival provocation tests in atopic dogs. Vet Ophthalmol. 2011;14(4): 248–56. doi.org/10.1111/j.1463-5224.2011.00874.x

Dupuis P, Prokopich CL, Hynes A, et al. A contemporary look at allergic conjunctivitis. Allergy Asthma Clin Immunolog. 2020;16(1): 5

Leonardi A. Allergy and allergic mediators in tears. Experimental Eye Research. 2013;117: 106–17. doi.org/10.1016/j.exer.2013.07.019

Hegeman SL, Bosin TR, Harrison SD. Fundamental concepts in ocular pharmacology. In: Clinical Ocular Pharmacology (eds) Bartlett JD, Jaanus SD. Boston: Butterworth Publishers. 1984: p. 3-35.

Etebu E, Arikekpar I. Antibiotics: Classification and mechanisms of action with emphasis on molecular perspectives. Int. Journal of Applied Microbiology and Biotechnology. 2016: 90-101

Sykes JE. Feline chlamydiosis. Clinical techniques in small animal practice. 2005;20(2): 129-134. doi.org/10.1053/j.ctsap.2004.12.018

Trope GE, Lawrence JR, Hind VM, et al. Systemic absorption of topically applied chloramphenicol eyedrops. Br J Ophthalmol.1979; 63(10), 690-691. doi.org/10.1136/bjo.63.10.690

Mitchel N, Oliver J. Ocular therapeutics. Feline Ophthalmology – The Manual, Centro empresarial El Trovador, Spain. 2015. p.32-40.

Ford, MM. Antifungals and their use in veterinary ophthalmology. Veterinary Clinics: Small Animal Practice. 2004;34(3): 669-691

Müller GG, Kara-José N, Castro RSD. Antifungals in eye infections: drugs and routes of administration. Revista Brasileira de Oftalmologia. 2013;72: 132-141. doi.org/10.1590/S0034-72802013000200014

Torres MA, Mohamed J, Cavazos-Adame H, et al. Topical ketoconazole for fungal keratitis. American Journal of Ophthalmology. 1985;100(2): 293-8. doi.org/10.1016/0002-9394(85)90795-0

Ishibashi Y. Miconazole and ketoconazole as a satisfactory first-line treatment for keratomycosis. American Journal of Ophthalmology.1986;102(4): 547-8. DOI: 10.1016/0002-9394(86)90103-0.

Gyanfosu L, Koffuor GA, Kyei S, et al. Efficacy and safety of extemporaneously prepared miconazole eye drops in Candida albicans-induced keratomycosis. International Ophthalmology. 2018;38: 2089-2100).

Sykes JE, Papich MG. Antiviral and immunomodulatory drugs. Canine and feline infectious diseases. 2014; 54.

Thomasy SM, Maggs DJ, Moulin NK, et al. Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats. American Journal of Veterinary Research. 2007;68: 1252-58. doi.org/10.2460/ajvr.68.11.1252

Fontenelle JP, Powell CC, Veir JK, et al. Effect of topical ophthalmic application of cidofovir on experimentally induced primary ocular feline herpesvirus-1 infection in cats. American Journal of Veterinary Research. 2008;69: 289-293. /doi.org/10.2460/ajvr.69.2.289

Sandmeyer LS, Keller CB, Bienzle D. Effects of cidofovir on cell death and replication of feline herpesvirus-1 in cultured feline corneal epithelial cells. American Journal of Veterinary Research. 2005;66: 217-222. doi.org/10.2460/ajvr.2005.66.217

Li SF, Gong MJ, Zhao FR, et al. Type I interferons: distinct biological activities and current applications for viral infection. Cellular Physiology and Biochemistry. 2018;51(5): 2377-96. doi.org/10.1159/000495897

Leaman DW, Rosebeck S, Borden EC. Biological and clinical properties of the type 1 interferons, In: immunotherapy of cancer, Ed: Disis ML, Humana Press Inc, NY, USA; 2006. DOI:10.1385/1-59745-011-1:365

Gould D. Feline herpesvirus-1: ocular manifestations, diagnosis and treatment options. Journal of feline medicine and surgery, 2011;13(5), 333-346. doi:10.1016/j.jfms.2011.03.010

Andrew SE. Ocular manifestations of feline herpesvirus. Journal of Feline Medicine and Surgery. 2001;3(1):9-16.doi: 10.1053/jfms.2001.0110

Horzinek MC, Addie D, Belak S, et al. Update of the 2009 guidelines on prevention and management of feline infectious diseases. Journal of Feline Medicine and Surgery. 2013;15: 530-539. doi.org/10.1177/1098612X13489

Trbolova A, 2013. Viral causes of uveitis in cats. e-Polish Journal of Veterinary Ophthalmology, 2:1-8

Kim JW, Lindsey JD, Weinreb RN. Increased human scleral permeability with prostaglandin exposure. Investigative Ophthalmology & Visual Science. 2001;42: 1514-21.

Subbulakshmi S, Kavitha S, Venkatesh R. Prostaglandin analogs in ophthalmology. Indian Journal of Ophthalmology. 2023;71(5): 1768-76. DOI: 10.4103/IJO.IJO_2706_22

Stephen C, Pflugfelder, MD (Chair). Management and therapy of dry eye disease: Report of the management and therapy subcommittee of the International Dry Eye WorkShop. The Ocular Surface. 2007;5(2): 163-178. doi: 10.1016/S1542-0124(12)70085-X.

Gelatt KN, Plummer CE. Essentials of Veterinary Ophthalmology. 4th ed. USA: John Wiley & Sons, Inc; 2022

Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review. Drug safety. 2002; 25, 233-250.

Borel, JF. History of the discovery of cyclosporin and of its early pharmacological development. The Wiener Klinische Wochenschrift. 2002;114: 433–437.

Colombo D, Ammirati E. Cyclosporine in transplantation–A history of converging timelines. Journal of Biological Regulators and Homeostatic Agents. 2011;25: 493–504

Enyedi, LB, Pearson, PA, Ashton P, et al. An intravitreal device providing sustained release of cyclosporine and dexamethasone. Current Eye Research.1996;15: 549-557. /doi.org/10.3109/02713689609000766

Jaffe GJ, Yang CS, Wang XC. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology. CrossRef. 1998;105: 46–56. doi.org/10.1016/S0161-6420(98)91176-9

Boothe DM. Small Animal Clinical Pharmacology and Therapeutics. 2nd ed. USA: Elsevier Saunders; 2012

Short, BG. Safety evaluation of ocular drug delivery formulations: Techniques and practical considerations. Toxicologic Pathology. 2008;36: 49-62. doi.org/10.1177/0192623307310955

Gelatt KN, Shlomo GB, Gilger BC, et al. Veterinary ophthalmology. 6th ed. Hoboken, NJ: Wiley‐Blackwell; 2020

Şen A, Akman TS. Regional Anesthesia in Ophthalmic Surgery. Kafkas Journal of Medical Sciences. 2023;13(2): 209-214. doi: 10.5505/kjms.2023.23427

Grahn BH, Storey ES. Lacrimostimulants and lacrimomimetics. Veterinary Clinics of North America: Small Animal Practice. 2004;34(3): 739-753

Ambati, J, Gragoudas ES, Miller JW, et al. Transscleral delivery of bioactive protein to the choroid and retina. Investigative Ophthalmology & Visual Science. 2000b;41: 1186-1191.

Colligris B, Crooke A, Huete-Toral F, et al. An update on dry eye disease molecular treatment: advances in drug pipelines. Expert Opinion on Pharmacotherapy. 2014;15(10): 1371-90. doi:10.1517/14656566.2014.914492

Gayathri K, Syam Kv. Glaucoma in Small Animals. Reviews of Veterinary. 2021; 40.

Cruysberg LPJ, Nuijts RMMA, Geroski DH, et al. The influence of intraocular pressure on the transscleral diffusion of high‐molecular‐weight compounds. Investigative Ophthalmology & Visual Science. 2005;46: 3790-3794. doi.org/10.1167/iovs.04-1414

Ashton, P, Podder SK, Lee VHL. Formulation influence on conjunctival penetration of four beta‐blockers in the pigmented rabbit. Pharmaceutical Research. 1991;8: 1166-1174. DOI: 10.1023/A:1015810619869.

Erichev VP, Makarova AS. Сompatibility of Systemic Drugs and Local Antihypertensive Therapy in Patients with Primary Open-Angle Glaucoma (Analytical Review). Ophthalmology in Russia. 2018;15(4): 366-373. doi.org/10.18008/1816-5095-2018-4-366-373

Aslam S, Gupta V. Carbonic anhydrase inhibitors. StatPearls Publishing. 2020. PMID: 32491668

Achim, HP, Woodward DF. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Survey of Ophthalmology, 2004;49(Suppl.1): 5-11. doi.org/10.1016/j.survophthal.2003.12.014

Aihara M, Lindsey JD, Weinreb RN. Enhanced FGF‐2 movement through human sclera after exposure to latanoprost. Investigative Ophthalmology & Visual Science. 2001;42: 2554-2559.